Madrigal Pharmaceuticals, Inc. (MDGL) Q3 2025 Earnings Call Transcript
Q3: 2025-11-04 Earnings Summary
EPS of -$4.96 misses by $2.96
| Revenue of $287.27M (362.03% Y/Y) beats by $39.57M
Madrigal Pharmaceuticals, Inc. (MDGL) Q3 2025 Earnings Call November 4, 2025 8:00 AM EST
Company Participants
Tina Ventura – Chief Investor Relations Officer
William Sibold – CEO, President & Director
David Soergel – Executive VP & Chief Medical Officer
Mardi Dier – Executive VP & CFO
Conference Call Participants
Yasmeen Rahimi – Piper Sandler & Co., Research Division
Jay Olson – Oppenheimer & Co. Inc., Research Division
Michael DiFiore – Evercore ISI Institutional Equities, Research Division
Akash Tewari – Jefferies LLC, Research Division
Thomas Smith – Leerink Partners LLC, Research Division
Andrea Tan – Goldman Sachs Group, Inc., Research Division
Ritu Baral – TD Cowen, Research Division
Jonathan Wolleben – Citizens JMP Securities, LLC, Research Division
Prakhar Agrawal – Cantor Fitzgerald & Co., Research Division
Srikripa Devarakonda – Truist Securities, Inc., Research Division
Kaveri Pohlman – Clear Street LLC
Presentation
Operator
Good morning, and thank you for standing by. Welcome to the Madrigal Pharmaceuticals Third Quarter 2025 Earnings Conference Call. [Operator Instructions] As a reminder, today’s conference call is being recorded.
I’d now like to introduce Ms. Tina Ventura, Chief Investor Relations Officer. Please go ahead.
Tina Ventura
Chief Investor Relations Officer
Thanks, Marvin. Good morning, everyone, and thank you for joining us to discuss Madrigal’s third quarter 2025 earnings. We issued a press release this morning and posted a slide deck that accompanies this webcast on the Investor Relations section of our website. On the call with me today is Bill Sibold, Chief Executive Officer; Dave Soergel, Chief Medical Officer; and Mardi Dier, Chief Financial Officer. They will provide prepared remarks, and then we’ll take your questions.
Please note on Slide 2, we will be making certain forward-looking statements today. We refer you to our SEC filings for a discussion of the risks that may cause actual results to differ from the forward-looking statements.
With that, I will now turn the
